Luye Pharma is a publicly traded Chinese pharma company operating 7 manufacturing sites with 30+ production lines and a pipeline of 40 domestic drug candidates plus 10+ international ones. The tech stack is heavy on SAP and manufacturing execution systems (MES), paired with Office productivity tools — typical for a regulated manufacturer managing GMP compliance and supply-chain complexity. Active hiring is sales-led (35 of 70 open roles), with decelerating velocity and recurring pain points around cold-chain tracking, GSP compliance, and cross-department coordination, suggesting post-manufacturing and commercial operations are under pressure.
Luye Pharma Group, founded in 1994 and headquartered in Shanghai, is an international pharmaceutical manufacturer with R&D centers in China, the U.S., and Europe. The company develops and manufactures drugs across oncology, cardiovascular, central nervous system, and metabolic therapies, with over 30 marketed products sold in more than 80 countries. Manufacturing spans 7 facilities with GMP certification and international quality standards; the product pipeline includes 40 domestic candidates and 10+ international candidates. Current focus areas include advanced drug delivery technologies (microspheres, liposomes, transdermal systems), antibodies, gene and cell therapies, and smart formulations.
Luye has 40 drug candidates in development in China and more than 10 overseas. Therapeutic focus areas are oncology, cardiovascular, central nervous system, and metabolism, with marketed portfolio covering 30+ products.
Luye operates 7 manufacturing sites globally with over 30 production lines in total, meeting GMP standards and international quality control. Active manufacturing hiring is concentrated in China and Malaysia.
Yes. Sales is the largest hiring function (35 of 70 active roles), though overall hiring velocity is decelerating. Open positions span China, Germany, and Malaysia.
Other companies in the same industry, closest in size